Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients

Journal of Analytical Toxicology

Volumn 36, Issue 4, 2012, Pages 232-238

  Yee, David A ^a   Best, Brookie M ^a,c   Atayee, Rabia S ^a,b   Pesce, Amadeo J ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d Millennium Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; OXYCODONE; OXYMORPHONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CREATININE URINE LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; PAIN; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RISK FACTOR; TANDEM MASS SPECTROMETRY; URINALYSIS; BIOLOGICAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REFERENCE VALUE; REPRODUCIBILITY; RETROSPECTIVE STUDY; TIME; URINE;

ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MODELS, BIOLOGICAL; OXYCODONE; OXYMORPHONE; PAIN; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84864550389     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bks022     Document Type: Article

References (22)

1. Cone, E.J., Fant, R.V., Rohay, J.M., Caplan, Y.H., Ballina, M., Reder, R.F. et al. (2003) Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. Journal of Analytical Toxicology, 27, 57-67.
2. Craig, D.S. (2010) Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain: A practical review for pharmacists. Pharmacy & Therapeutics, 35, 324-357.
3. Ross, F.B., Smith, M.T. (2007) The intrinsic antinociceptive effects of oxycodone appear to be l-opioid receptor mediated. Pain, 73, 151-157.
4. Samer, C.F., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C.B., Rebsamen, M.C. et al. (2010) Genetic polymorphism and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. British Journal of Clinical Pharmacology, 160, 916-930.
5. Trescot, A.M., Datta, S., Lee, M., Hansen, H. (2008) Opioid pharmacology. Pain Physician, 11, S133-S153.
6. Prommer, E. (2005) Oxymorphone: A review. Supportive Care in Cancer, 14, 109-115.
7. Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liuchen, L., Shen, D.D. (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clinical Pharmacology and Therapeutics, 79, 461-479.
8. Model Policy for the Use of Controlled Substances for the Treatment of Pain. House of Delagates of the Federation of State Medical Boards of the United States, Inc. (2004) http://www.fsmb.org/pdf/2004_grpol_controlled_substances.pdf (accessed May 25, 2010).
9. Trescot, A.M., Boswell, M.V., Atluri, S.L., Hansen, H.C., Deer, T.R., Abdi, S. et al. (2006) Opioid guidelines in the management of chronic non-cancer pain. Pain Physician, 9, 1-40.
10. Chou, R., Fanciullo, G.J., Fine, P.G., Adler, J.A., Ballantyne, J.C., Davies, P. et al. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. Journal of Pain, 10, 113-130.
11. Cook, J.D., Caplan, Y.H., LoDico, C.P., Bush, D.M. (2000) The characterization of human urine for specimen validity determination in workplace drug testing: A review. Journal of Analytical Toxicology, 24, 579-588.
12. Heit, H.A., Gourlay, D.L. (2004) Urine drug testing in pain medicine. Journal of Pain Symptom Management, 27, 260-267.
13. Cone, E.J., Darwin, W.D., Buchwald, W.F., Gorodetzky, C.W. (1983) Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metabolism and Disposition, 11, 446-450.
14. Pöyhiä, R., Seppälä, T., Olkkola, K.T., Kalso, E. (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British Journal of Clinical Pharmacology, 33, 617-621.
15. Baselt, R.C. (2008) Disposition of toxic drugs and chemicals in man, 8th edition. Biomedical Publications, Foster City, CA, pp. 1166-1168.
16. Fishbain, D.A., Fishbain, D., Lewis, J., Cutler, R.B., Cole, B., Rosomoff, H.L., Rosomoff, R.S. (2004) Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time? A structured review. Pain Medicine, 5, 81-93.
17. Lalovic, B., Phillips, B., Risler, L.L., Howald, W., Shen, D.D. (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metabolism and Disposition, 32, 447-454.
18. Sistonen, J., Fuselli, S., Palo, J.U., Chauhan, N., Padh, H., Sajantila, A. (2009) Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenetics and Genomics, 19, 170-179.
19. Somogyi, A.A., Barratt, D.T., Coller, J.K. (2007) Pharmacogenetics of opioids. Clinical Pharmacology and Therapeutics, 81, 429-444.
20. Stamer, U.M., Bayerer, B., Stüber, F. (2005) Genetics and variability in opioid response. European Journal of Pain, 9, 101-104.
21. Wolf, B.C., Lavezzi, W.A., Sullivan, L.M., Flannagan, L.M. (2005) One hundred seventy two deaths involving the use of oxycodone in Palm Beach County. Journal of Forensic Sciences, 50, 192-195.
22. Kaiko, R.F., Benziger, D.P., Fitzmartin, R.D., Burke, B.E., Reder, R.F., Goldenheim, P.D. (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clinical Pharmacology and Therapeutics, 59, 52-61.